Forward Looking Statements This presentation contains - - PowerPoint PPT Presentation

Investor

Presentation

MARCH

2017 2017

Accelerating Biomedical Technologies from Incubation to Monetization

QBIO

Forward Looking Statements

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. (“QBIO”) or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those project these forward-looking statements are made as of the date of this presentation, and we assume no obligation to update any forward-looking statements due to numerous factors. forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein, and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed, Inc

• companies. (“QBIO”) may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.

Biotech Growth &The Problem It Created

QBioMed Solves It by Accessing Undiscovered

Biomedical Technologies for Investment t

Pharma sales continue on a five-year growth track and is expected long term. An aging population provides consistent demand and high growth rates. Demand for affordable drugs remains inelastic. International market growth creates a positive Global Market Growth Estimate

The Biotech & The Life Science Sectors

200 400 600 800 1000 1200

2010 2011 2012 2013 2014 2015 Sales $M 60+ Population

Pharma Sales Linked to 60+ Population

However, the reality for many is

approximately 8 out of 10 biomedical ideas

are under-recognized and under-capitalized. Only very few have access to capital leaving viable ideas unfunded and neglected.

Sources: UNDESA Population and Pharmafile

50 100 150 200 250 300 350 400 450 500

2015 2016 2017 2018 2019 USD $B

Global Biotech Market Estimate

Sources: UNDESA Population and Pharmafile

• p. 4

• f biomedical start ups lack capital and resources to

transition from incubation to development and beyond.

Reasons

Too small Unrealistic goals Unproven IP/ formulation Missed milestones Not ready to go public Previous financing Cannot attract / retain talent Not attracting partnerships

80 80

The Result

Billions of dollars in market value remain locked in academia, early- stage IP, unfocused management, challenging capital structures and failed IPOs. Investors cannot access them. They live in limbo or stuck in ‘dead money’ investments.

The Problem

%

QBioMed Solves the Problem by

availing capital to develop biomedical technologies while also providing investors access to participate in

• ur assets' growth and value.
• p. 5

Our vision is to create a pipeline of innovative biomedical assets in various

stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our assets' technologies to monetization.

Asset Search and Due Diligence Ongoing Since Inception

Management Team

GRAH 1

Denis Denis Corin Corin William illiam Rosenstadt

• senstadt

Da David vid Lask Laskow-Pooley

• oley

Ari Ari Jatw twes es

Chief Executive Officer Chairman of the Board General Counsel Director VP Product Development Director Analyst Director

Advisory Board

• Dr. Geert Cauwenberg

Dermatology, Wound, Infectious Diseases, Women’s Health

• Dr. Helga Grupe

Oncology

• Dr. Jose de Chastonay

Contract Services

• Dr. Scott P Bruder

Medical Devices, Orthopedics and Regenerative Medicine Andy Watson Diagnostics, Companions, Genomics, Life Science Tools John Erb Medical Device Cardio Vascular Mary Jan Rafii Ophthalmology

• Dr. Susan Quaggin

CSO, Manin Resarch George Nikopoulos CEO, Mannin Research Rosanne Satz CEO, BioNucleonics,

• Dr. Stanley Satz

Chairman, BioNucleonics Jean-Jaques Mondoloni Advisor Wombat Capital

Our Milestones

August

Established Management Team

June Initiated new business model October

MAN-01 Exclusive License Option

February

SR89 Exclusive License Option LOI

April

MAN-01 Molecule Opt.

September

Closes SR89 License Option

November $4 M Financing September

Engages Wombat Capital as Scientific Advisor

Planned 1Q 2017 initial Sr89 production

2015 2016 2017

• p. 7

We unlock capital through US public markets to fund the development of our assets. We make liquid investments in high-value assets that can produce exponential returns. We diversifiy risk over several therapies in various stages of development and deploy performance- based capital only. We accelerate our assets' development with our management and advisory teams' expertise, experience, and industry relationships.

How We Accelerate Biomedical Technology Development

Our ownership of an asset and our ROI steadily increase as assets hit milestones and cross value-creating events during development lifecycles.

Our Business Model

INVEST

Capital attached to goals

ACCELERATE

Increase investment and ownership

MONETIZE

Operate, partner, license, IPO or sell

Preliminary scientific and commercial criteria review. Determining management's expectations and flexibility moves the asset to the next step. Due diligence is combined with a validation of management's development and capital requirements. Performance-based capital is deployed to meet specific and mutually-agreed goals in each stage. Additional resources are infused to move the asset through development stages and to a value-creating inflection point. Assets can be sold, licensed, joint-ventured or operated as cash flow positive product lines. QBIO's goal is to maximize value for its shareholders.

IDENTIFY

Criteria match and fit

ANALYZE

Asset and development plan

The Importance of an Asset's Development Plan

Development plans provide QBio a tool to assess management's work to date and an insight into an asset's biomedical technology and value. The plan should have clearly defined milestones and quantify capital needed to accelerate development. QBIO's Team and Advisors can pinpoint their resources to help transition a plan through development to monetization.

Managing to milestones mitigates investment risk. QBio's capital is released only when milestones are met.

A Requirement to Access QBio Capital

Drug Candidate Preclinical Phase 1 Phases 1b/2a Phase 3 Approval

A Growing Pipeline Mitigates Risk and Drives Shareholder Value

In YEARS 1&2 we are focused on licensing and acquiring assets, some with near term (6-12 months) REVENUE or value-creating opportunities. In YEARS 2&3 we will look to grow the pipeline and monetize investments through partnerships, JV, IPO and sales revenue growth. ASSET 1

SR-89 Radiopharmaceutical

ASSET 2

MAN – 01 Topical Eye Drops

TARGET ASSET 4 TARGET ASSET 5 Protocol Design for Ph4 ASSET 3

UTTROCIDE-B Chemotherapy

TARGET ASSET 6 IND Preparation for Ph2/3

• p. 11

Drug Candidate 505(b)2 Preclinical Phase 1 Phases 2/3 Phase 4 Approval

Our Current Portfolio of High-Value Assets

Strontium Chloride Sr89

Injection, USP

FDA-Approved, Commercialization Planning and Accelerating Development of Additional Large-Market Therapies

UTTROCIDE-B

Pharmaceutical: Generic SR-89 Radiopharmaceutical Condition: Bone Cancer Therapy and Pain Management Addressable Market: ~110,000 yearly diagnoses from breast and prostate cancers Technology BioNucleonics Stage:

• Approved

Commercializing

Asset 1

Strontium Chloride Sr89

Injection, USP

BONE METASTESES

from Prostate and Breast Cancer

▪ Pain is the most common sign of bone cancer, and may become more noticeable as the tumor grows. ▪ Bone pain can cause a dull or dull or deep ac deep ache he in a bone

• r bone region (e.g., back, pelvis, legs, ribs, arms).

▪ Treatment options include:

Pain Medications - Opioids Orthopedic Procedures Radiation Therapy Radiopharmaceuticals

▪ Sr89 is Sr89 is NON NON-NAR ARCO COTI TIC C and can mitiga and can mitigate opi te opioid

• id

use and a use and abuse buse

Pain Management

▪ 450,000* new breast and prostate cases are recorded each year ▪ 1 in 3 people 1 in 3 people will develop bone metastases from the spread of breast and prostate cancer

*Source: American Cancer Society, 2016

• p. 14

Market Potential for Bone Cancer Pain Palliation is

Estimated at $60-$80 Million

How it works

Drug targets bone-cancer afflicted areas providing direct radiation to destroy active cancer cells and relieve symptoms. Effective In 70% of patients, usually within two weeks and can last six months.

▪ Indicated to relieve bone pain from skeletal metastases from breast and prostate cancers ▪ Can be used with opioid based drugs and cancer therapeutics ▪ Studies demonstrated a prolonged progression- free result and overall survival with acceptable toxicity

• p. 15

Strontium Chloride Sr89

Injection, USP

Non Opioid Pain Medication

Pharmaceutical: MAN-01 Topical Drops Condition: Glaucoma Addressable Market: 60 million patients worldwide Technology Stage: Exiting Preclinical

MAN-01

Asset 2

60 60 mil milli lion

• n pa

patien tients ts worldwide 8 mil 8 milli lion

• n with bilateral blindness

Typically no early warning signs The herapy y on

• nly

y sl slows ws pr prog

• gress

ession ion

GLAUCOMA

A Devastating Condition with No Cure

Vision with Glaucoma

Current Standards of Care

Med Medical ical (Ph (Phar armac maceu eutica ticals) ls) No new glaucoma pharmaceutical in 20 years (1996) La Lase ser r Sur urge gery y (O (Out ut-pa patient) tient) Requires two procedures and use of pharmaceuticals Trad aditi ition

• nal

al Sur urge gery y (I (In-pa patient) tient) Requires two procedures and use of pharmaceuticals Painful, costly, and invasive

Normal vision

• p. 17

60.5 79.6

10 20 30 40 50 60 70 80 90

2010 2020

Drug (Company) Target/MOA Stage

BOL-303259 (Bausch + Lomb) NO-donating latanoprost Phase 3 K115 (Kowa) ROCK Inhibitor Phase 3 DE-117 (Santen) EP2 agonist Phase 2a ONO-9054 (Ono) FP/EP3 agonist Phase 1 AMA0076 (Amakem) ROCK Inhibitor Phase 2a LX7101 (Lexicon) LIMK2 inhibitor Phase 1/2 SYL040012 (Sylentis) RNAi beta blocker Phase 2 AR-13324 (Aerie) ROCK/NET Inhibitor Phase 3

▪ First in class drug for Intraocular Eye Pressure

No new drugs in "IOP" for 20 years

▪ Only drug targeting the critical ‘Schlemms’ Canal

The Schlemms Canal is responsible for 70%-90% of fluid drainage in the eye

▪ Testing results shows normalizing IOP ▪ Primary indication for Adult Open Angle Glaucoma

Additional indications may include:

• Age Related Macular Degeneration (AMD)
• Cystic Kidney Disease

▪ Mannin Research accepted into Johnson & Johnson Innovation, JLABS @ Toronto

Partnership to develop a novel eye-drop to treat Primary Open- Angle Glaucoma utilizing the Tie2 Mechanism of Action

Trea eatme tment C nt Com

• mpar

parativ tive A e Anal nalysis is

None of the follow address the Schlemms Canal

Source: W.H.O. 2010

Glaucoma laucoma Cas Cases es Expected xpected to to Incr ncreas ease 30% e 30% by by 2020 2020

(millions of cases)

▲ 30% Increase in Cases

Glaucoma Drug

Pu Public blic Mar Market et Comp Comp

Aerie Pharmaceuticals - AERI $1.5 b MCAP

MAN-01

• p. 18

Pharmaceutical: Uttrocide-B Condition: Liver Cancer Addressable Market: 700,0000 diagnoses per year Technology: Chemotherapy Stage: Exiting Preclinical

UTTROCIDE-B

Asset 3

Esti Estima mate ted d 39 39,230 ,230 ad adults ults in the United States will be diagnosed every year Sho Short t 1-yea ear r survival rate Mo More th e than an 700 700,000 ,000 pe peop

• ple

le wor

• rld

ldwide wide are diagnosed each year

LIVER CANCER

10 10th

th Most

• st Commo
• mmon

n Can ance cer

Current Standards of Care

Su Surgical gical Hepatectomy or Liver Transplantation The hermal mal Abla blation tion Radiofrequency ablation (RFA) and microwave therapy Per ercu cutan taneo eous us eth ethan anol

• l injection

injection Alcohol is injected directly into the liver tumor Radia Radiation tion High-energy x-rays or other particles destroy cancer cells Drug ug Trea eatmen tment

tryosine kinase inhibitor antineoplastic agent, Nexavar™

• p. 20

500 5800

1000 2000 3000 4000 5000 6000 Uttrocide-B Sorafenib

Sorafenib Tosylate (Nexavar™) is the only FDA approved drug for the treatment of liver cancer

P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis in liver cancer)

A natural compound Fractionated Saponin derived from S. nigrum Small molecule Steriod Glycoside

Uttroside B increases the cytotoxicity of a variety

• f liver cancer cell types

Up to 10x more potent than Sorafenib in pre clinical studies

Cytotoxicity specific to cancerous liver cells Provisional patent filed

Chemotherapy

OMRF’S Solution

A compound that increases cytotoxicity in liver cancer cells by increased apoptosis and decreased pro survival signaling

UTTROCIDE-B

IN VITRO IC IC-50 50 of

• f Sor
• raf

afenib enib is is 5.8 5.8 uM uM in H in Hep ep G2 w 2 while hile Uttr ttrocide

• cide-B

B is is 500 500 IN VIVO HepG epG2 I 2 Injected njected Into M nto Mice T ice Then T hen Trea eated ted with 10mg ith 10mg of

• f Uttr

ttrocide

• cide-B

B for O

• r One M

ne Month

• nth

20 40 60 80 100 120 140 160 Week 1 Week 2 Week 3 Week 4 Control Uttrocide B

• p. 21

100,000 200,000 300,000 400,000 500,000 600,000 $0.00 $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 $7.00 $8.00 12/5/2016 1/4/2017 2/3/2017

News Flow

Q Biomed Joins with Oklahoma Medical Research Foundation and Rajiv Gandhi Centre for Biotechnology to Develop Liver Cancer Chemotherapeutic Q BioMed Inc. Announces Mannin Research Accepted Into Johnson & Johnson Innovation, JLABS @ Toronto Q BioMed Inc. Announces Entry Into Definitive Funding Agreement for up to $4,000,000 Q BioMed Inc. Technology Partner Mannin Research Inc. to Participate in a Webcast on Innovating for Ophthalmic Diseases Q BioMed Drug Development Partner to Attend EANM 2016 in Barcelona, Spain October 15-19 2016 Q BioMed Partner Mannin Research Executives Attending OIS@AAO 2016 & AAO

QBIO

3-Month Trading History

As of March 1, 2017

Shares Outstanding Warrants

Data as of 11.30.16

9,200,000 1 M

Market Cap

~$40 M

Inside Ownership

35%

• Avg. Volume

125,421

Float

5,775,000

Yearend

November 30

PRICE

VOLUME

Recent Conferences

January 2017

Biotech Showcase, San Francisco

$3.95

• p. 22

Low Float ● Tightly Held ● Ownership

Attractive entry level valuation Current assets and acquisitions value Revenue in enue in 1H 1H17 17

Launch and commercialize FDA- Approved SR89

Revenue generation expected in 1H17

Accelerate MAN-01 Asset Development

Molecule optimization

Up list to National exchange in 1H 2017 Complete pre-clinical and Prepare IND for Uttrocide-B in Liver Cancer Add one or two additional asset licenses in 2017

What to Expect From Us

1 2 3 4

QBIO

• p. 23

5

Corporate

501 Madison Avenue New York, NY 10222 USA

+1 (888) 357-2435

Executive & Investors Denis Corin, CEO dcorin@qbiomed.com

Accelerating Biomedical Technologies from Incubation to Monetization

QBIO